JP2010516626A5 - - Google Patents

Download PDF

Info

Publication number
JP2010516626A5
JP2010516626A5 JP2009545734A JP2009545734A JP2010516626A5 JP 2010516626 A5 JP2010516626 A5 JP 2010516626A5 JP 2009545734 A JP2009545734 A JP 2009545734A JP 2009545734 A JP2009545734 A JP 2009545734A JP 2010516626 A5 JP2010516626 A5 JP 2010516626A5
Authority
JP
Japan
Prior art keywords
cancer
cyclodextrin
pharmaceutical composition
composition according
iodo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009545734A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010516626A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/051214 external-priority patent/WO2008089272A1/en
Publication of JP2010516626A publication Critical patent/JP2010516626A/ja
Publication of JP2010516626A5 publication Critical patent/JP2010516626A5/ja
Withdrawn legal-status Critical Current

Links

JP2009545734A 2007-01-16 2008-01-16 ガン治療剤 Withdrawn JP2010516626A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88075507P 2007-01-16 2007-01-16
PCT/US2008/051214 WO2008089272A1 (en) 2007-01-16 2008-01-16 Formulations for cancer treatment

Publications (2)

Publication Number Publication Date
JP2010516626A JP2010516626A (ja) 2010-05-20
JP2010516626A5 true JP2010516626A5 (enExample) 2011-03-03

Family

ID=39350967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009545734A Withdrawn JP2010516626A (ja) 2007-01-16 2008-01-16 ガン治療剤

Country Status (32)

Country Link
US (1) US20080176946A1 (enExample)
EP (2) EP2121139B1 (enExample)
JP (1) JP2010516626A (enExample)
KR (1) KR20090113852A (enExample)
CN (1) CN101668561A (enExample)
AU (1) AU2008206294A1 (enExample)
BR (1) BRPI0806590A2 (enExample)
CA (1) CA2674600A1 (enExample)
CO (1) CO6220840A2 (enExample)
CR (1) CR10975A (enExample)
CY (1) CY1113819T1 (enExample)
DK (1) DK2121139T3 (enExample)
DO (1) DOP2009000178A (enExample)
EC (1) ECSP099577A (enExample)
ES (1) ES2395690T3 (enExample)
GB (1) GB2447796C (enExample)
GT (1) GT200900201A (enExample)
HR (1) HRP20120960T1 (enExample)
IL (1) IL199682A0 (enExample)
MA (1) MA34559B1 (enExample)
MX (1) MX2009007596A (enExample)
NZ (1) NZ579098A (enExample)
PL (1) PL2121139T3 (enExample)
PT (1) PT2121139E (enExample)
RS (1) RS52633B (enExample)
RU (2) RU2481830C2 (enExample)
SG (1) SG178714A1 (enExample)
SI (1) SI2121139T1 (enExample)
SV (1) SV2009003335A (enExample)
TN (1) TN2009000292A1 (enExample)
UA (1) UA100852C2 (enExample)
WO (1) WO2008089272A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7961081B2 (en) * 2003-05-22 2011-06-14 John Tomlienovic Anti-theft system and method
CN101233121A (zh) * 2005-06-10 2008-07-30 彼帕科学公司 Parp调节剂和癌症的治疗
ZA200800907B (en) 2005-07-18 2010-04-28 Bipar Sciences Inc Treatment of cancer
JP2010504079A (ja) * 2006-06-12 2010-02-12 バイパー サイエンシズ,インコーポレイティド Parp阻害剤を用いる疾病の治療方法
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
WO2008030892A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
CN101534836B (zh) 2006-09-05 2011-09-28 彼帕科学公司 Parp抑制剂在制备治疗肥胖症的药物中的用途
WO2008030883A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
CN101903025A (zh) * 2007-10-19 2010-12-01 彼帕科学公司 利用苯并吡喃酮-型parp抑制剂治疗癌症的方法和组合物
US7732491B2 (en) 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
MX2010008572A (es) * 2008-02-04 2010-11-30 Bipar Sciences Inc Metodos de diagnostico y tratamiento de enfermedades mediadas por poli(adp-ribosa) polimerasa.
US8026271B2 (en) * 2008-07-11 2011-09-27 National Health Research Institutes Formulations of indol-3-yl-2-oxoacetamide compounds
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
MX2011003277A (es) * 2008-10-14 2012-09-21 Salubrious Pharmaceuticals LLC Proceso para el tratamiento de la artritis reumatoide, temblores/enfermedad de parkinson, esclerosis multiple y cancer de tipo no viral.
EP2709618A4 (en) * 2011-05-10 2014-11-05 UNIVERSITé LAVAL METHOD FOR THE TREATMENT AND DIAGNOSIS OF PULMONARY ARTERIAL HYPERTENSION
PL2925299T3 (pl) * 2012-11-30 2018-11-30 Novartis Ag Nowa kompozycja farmaceutyczna
WO2017192618A1 (en) * 2016-05-02 2017-11-09 Symbios Technologies, Inc. Electrochemical plasma activated aqueous chemotherapeutics
US11433074B2 (en) 2017-06-22 2022-09-06 Triact Therapeutics, Inc. Methods of treating glioblastoma
TWI843707B (zh) 2017-09-26 2024-06-01 美商提薩羅有限公司 尼拉帕尼(niraparib)調配物
EP3687501A4 (en) * 2017-09-29 2021-06-23 Triact Therapeutics, Inc. INIPARIB FORMULATIONS AND THEIR USES
US12295938B2 (en) 2019-06-04 2025-05-13 Samsung Life Public Welfare Foundation Composition for treating castration-resistant prostate cancer, comprising quassinoids
CZ309587B6 (cs) * 2021-01-22 2023-05-03 Oncora S.R.O. Mikroemulzní prekoncentrát s obsahem kladribinu a způsob jeho přípravy
GB2611315B (en) * 2021-09-29 2024-01-03 Siemens Healthcare Gmbh Method of operating a magnetic resonance scanner
US20250372199A1 (en) * 2022-06-10 2025-12-04 Dana-Farber Cancer Institute, Inc. Allelic imbalance of chromatin accessibility in cancer identifies causal risk variants and their mechanisms

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0348655A (ja) * 1989-07-14 1991-03-01 Shionogi & Co Ltd プロスタグランジンd↓2類の安定化
US5633282A (en) * 1990-05-25 1997-05-27 British Technology Group Limited Inhibition of viral infection
US5637618A (en) * 1990-06-01 1997-06-10 Bioresearch, Inc. Specific eatable taste modifiers
US5631038A (en) * 1990-06-01 1997-05-20 Bioresearch, Inc. Specific eatable taste modifiers
US5232735A (en) * 1990-06-01 1993-08-03 Bioresearch, Inc. Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers
US5484951A (en) * 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5516941A (en) * 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
US5877185A (en) * 1991-10-22 1999-03-02 Octamer, Inc. Synergistic compositions useful as anti-tumor agents
US5753674A (en) * 1991-10-22 1998-05-19 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents, anti-retroviral agents and anti-tumor agents
US5464871A (en) * 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5482975A (en) * 1991-10-22 1996-01-09 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
US5558855A (en) 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
US6015792A (en) * 1993-05-26 2000-01-18 Bioresearch, Inc. Specific eatable taste modifiers
US6008250A (en) * 1993-05-26 1999-12-28 Bioresearch, Inc. Specific eatable taste modifiers
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
AU5780696A (en) * 1995-06-02 1996-12-18 Takeda Chemical Industries Ltd. Stabilized composition comprising an antiulcerative benzimid azole
US5837729A (en) * 1996-04-26 1998-11-17 Metatron, Inc. Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof
JP4001636B2 (ja) * 1997-04-10 2007-10-31 アイソテクニカ,インコーポレイテッド ガンおよびaidsの処置のための活性化ヨード誘導体
US5908861A (en) * 1997-05-13 1999-06-01 Octamer, Inc. Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US6696426B2 (en) * 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
RU2003119972A (ru) * 2001-01-04 2004-12-27 Дайити Фармасьютикал Ко., Лтд. (JP) Препараты циклодекстрина
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
JP2003321364A (ja) * 2002-05-07 2003-11-11 Eisai Co Ltd シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物
JP2006516034A (ja) * 2003-01-14 2006-06-15 テバ ファーマシューティカル インダストリーズ リミティド 全身性エリテマトーデスを治療するためのペプチドの非経口製剤
WO2005023765A1 (en) * 2003-09-11 2005-03-17 Pharmacia & Upjohn Company Llc Method for catalyzing amidation reactions by the presence of co2
CN101233121A (zh) * 2005-06-10 2008-07-30 彼帕科学公司 Parp调节剂和癌症的治疗
ZA200800907B (en) * 2005-07-18 2010-04-28 Bipar Sciences Inc Treatment of cancer
JP2010504079A (ja) * 2006-06-12 2010-02-12 バイパー サイエンシズ,インコーポレイティド Parp阻害剤を用いる疾病の治療方法
WO2008030887A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
CN101534836B (zh) * 2006-09-05 2011-09-28 彼帕科学公司 Parp抑制剂在制备治疗肥胖症的药物中的用途
WO2008030892A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
WO2008030883A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer

Similar Documents

Publication Publication Date Title
JP2010516626A5 (enExample)
RU2481830C2 (ru) Лекарственные препараты для лечения рака
JP2017530171A5 (enExample)
JP2013522292A5 (enExample)
RU2010128107A (ru) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
JP2016040288A5 (enExample)
JP2024511996A5 (enExample)
JP2013545812A5 (enExample)
JP2018510139A5 (enExample)
HRP20251115T1 (hr) Metode i spojevi za obnavljanje funkcije mutanta p53
JP2018518537A5 (enExample)
JP2013534535A5 (enExample)
JP2014012726A5 (enExample)
JP2017517538A5 (enExample)
CU23967B1 (es) Derivados de pirazin-2-carboxamida para tratar enfermedades mediadas por el bloqueo del canal de sodio epitelial
BRPI0918010B8 (pt) conector para recipiente descartável para ser usado em máquinas de diálise
JP2010514797A5 (enExample)
JP2008525530A5 (enExample)
RU2015154275A (ru) Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf
JP2018505880A5 (enExample)
JP2013537203A5 (enExample)
JP2009534457A5 (enExample)
JP2016525130A5 (enExample)
RU2016122731A (ru) Функционализированные и замещенные индолы в качестве противораковых агентов
JP2010540555A5 (enExample)